Last reviewed 2026-05-14 · How we verify

GDC-0853 and itraconazole

Genentech, Inc. · Phase 1 active Small molecule

GDC-0853 and itraconazole is a Small molecule drug developed by Genentech, Inc.. It is currently in Phase 1 development.

At a glance

Generic name	GDC-0853 and itraconazole
Sponsor	Genentech, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GDC-0853 and itraconazole CI brief — competitive landscape report
GDC-0853 and itraconazole updates RSS · CI watch RSS
Genentech, Inc. portfolio CI

Frequently asked questions about GDC-0853 and itraconazole

What is GDC-0853 and itraconazole?

GDC-0853 and itraconazole is a Small molecule drug developed by Genentech, Inc..

Who makes GDC-0853 and itraconazole?

GDC-0853 and itraconazole is developed by Genentech, Inc. (see full Genentech, Inc. pipeline at /company/genentech-inc).

What development phase is GDC-0853 and itraconazole in?

GDC-0853 and itraconazole is in Phase 1.

Manufacturer: Genentech, Inc. — full pipeline
Compare: GDC-0853 and itraconazole vs similar drugs
Pricing: GDC-0853 and itraconazole cost, discount & access